CADL Insider Trading
Insider Ownership Percentage: 41.60%
Insider Buying (Last 12 Months): $7,500,000.00
Insider Selling (Last 12 Months): $1,223,059.51
Candel Therapeutics Share Price & Price History
Current Price: $9.05
Price Change: ▲ Price Increase of +0.23 (2.61%)
As of 02/14/2025 05:00 PM ET
Candel Therapeutics Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
1/15/2025 | Francesca Barone | Insider | Sell | 13,534 | $7.22 | $97,715.48 | 110,673 | |
1/15/2025 | Seshu Tyagarajan | CTO | Sell | 14,322 | $7.22 | $103,404.84 | 96,790 | |
1/8/2025 | Francesca Barone | Insider | Sell | 13,673 | $8.22 | $112,392.06 | 124,207 | |
12/16/2024 | Paul B Manning | Director | Buy | 1,250,000 | $6.00 | $7,500,000.00 | 1,303,752 | |
11/29/2024 | Seshu Tyagarajan | CTO | Sell | 20,392 | $4.56 | $92,987.52 | 125,657 | |
11/29/2024 | William Garrett Nichols | Insider | Sell | 13,935 | $4.56 | $63,543.60 | 100,547 | |
10/14/2024 | Estuardo Aguilar-Cordova | Major Shareholder | Sell | 15,000 | $6.02 | $90,300.00 | 929,873 | |
10/11/2024 | Estuardo Aguilar-Cordova | Major Shareholder | Sell | 15,000 | $6.05 | $90,750.00 | 944,873 | |
10/3/2024 | Estuardo Aguilar-Cordova | Major Shareholder | Sell | 1,800 | $6.85 | $12,330.00 | 959,873 | |
7/17/2024 | Charles Schoch | Insider | Sell | 9,884 | $6.47 | $63,949.48 | 62,520 | |
7/17/2024 | Paul Peter Tak | CEO | Sell | 22,528 | $6.47 | $145,756.16 | 330,735 | |
7/17/2024 | Seshu Tyagarajan | CTO | Sell | 14,851 | $6.47 | $96,085.97 | 146,049 | |
7/11/2024 | Charles Schoch | Insider | Sell | 8,897 | $5.97 | $53,115.09 | 72,404 | |
7/11/2024 | Paul Peter Tak | CEO | Sell | 20,293 | $5.97 | $121,149.21 | 353,263 | |
7/11/2024 | Seshu Tyagarajan | CTO | Sell | 13,330 | $5.97 | $79,580.10 | 160,900 | |
12/8/2022 | Francesca Barone | Insider | Buy | 1,238 | $1.61 | $1,993.18 | 2,738 | |
12/8/2022 | Jason Amello | CFO | Buy | 3,100 | $1.69 | $5,239.00 | 3,100 | |
12/8/2022 | Joseph C Papa | Director | Buy | 3,014 | $1.70 | $5,123.80 | 3,014 | |
12/8/2022 | Paul Peter Tak | CEO | Buy | 3,050 | $1.70 | $5,185.00 | 28,050 | |
12/8/2022 | Seshu Tyagarajan | CTO | Buy | 3,000 | $1.69 | $5,070.00 | 3,000 | |
Candel Therapeutics Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
2/14/2025 | Northern Trust Corp | 165,021 | $1.43M | 0.0% | +3.9% | 0.508% |  |
2/14/2025 | Oxford Asset Management LLP | 12,003 | $0.10M | 0.1% | N/A | 0.037% |  |
2/14/2025 | Birchview Capital LP | 60,000 | $0.52M | 0.4% | N/A | 0.185% |  |
2/14/2025 | Heights Capital Management Inc. | 30,000 | $0.26M | 0.1% | N/A | 0.092% |  |
2/14/2025 | MetLife Investment Management LLC | 13,773 | $0.12M | 0.0% | +9.7% | 0.042% |  |
2/13/2025 | Portolan Capital Management LLC | 753,745 | $6.54M | 0.4% | N/A | 2.321% |  |
2/13/2025 | Barclays PLC | 34,317 | $0.30M | 0.0% | +19.6% | 0.106% |  |
2/13/2025 | Russell Investments Group Ltd. | 3,753 | $33K | 0.0% | +75.1% | 0.012% |  |
2/13/2025 | Wells Fargo & Company MN | 10,122 | $88K | 0.0% | +63.6% | 0.031% |  |
2/12/2025 | Geode Capital Management LLC | 455,424 | $3.95M | 0.0% | +1.4% | 1.402% |  |
2/12/2025 | JPMorgan Chase & Co. | 10,426 | $90K | 0.0% | +15.2% | 0.032% |  |
2/11/2025 | LPL Financial LLC | 10,703 | $93K | 0.0% | N/A | 0.033% |  |
2/11/2025 | Halter Ferguson Financial Inc. | 681,334 | $5.91M | 2.4% | +123.7% | 2.098% |  |
2/10/2025 | Commonwealth Equity Services LLC | 41,098 | $0.36M | 0.0% | N/A | 0.127% |  |
2/6/2025 | Charles Schwab Investment Management Inc. | 52,190 | $0.45M | 0.0% | +11.6% | 0.161% |  |
2/5/2025 | Oppenheimer & Co. Inc. | 37,915 | $0.33M | 0.0% | N/A | 0.117% |  |
1/30/2025 | Rhumbline Advisers | 26,272 | $0.23M | 0.0% | +17.0% | 0.081% |  |
1/30/2025 | Vontobel Holding Ltd. | 19,000 | $0.17M | 0.0% | -13.6% | 0.058% |  |
1/15/2025 | HB Wealth Management LLC | 87,300 | $0.70M | 0.0% | +54.1% | 0.269% |  |
12/26/2024 | JPMorgan Chase & Co. | 9,051 | $63K | 0.0% | -53.2% | 0.028% |  |
11/19/2024 | Barclays PLC | 28,688 | $0.20M | 0.0% | +327.1% | 0.088% |  |
11/16/2024 | Geode Capital Management LLC | 448,997 | $3.11M | 0.0% | +12.8% | 1.399% |  |
11/15/2024 | Barclays PLC | 28,688 | $0.20M | 0.0% | +327.1% | 0.089% |  |
11/15/2024 | MML Investors Services LLC | 22,313 | $0.16M | 0.0% | -69.6% | 0.070% |  |
11/15/2024 | State Street Corp | 492,005 | $3.41M | 0.0% | +4.1% | 1.534% |  |
11/15/2024 | Atom Investors LP | 14,873 | $0.10M | 0.0% | N/A | 0.046% |  |
11/14/2024 | MetLife Investment Management LLC | 12,558 | $87K | 0.0% | N/A | 0.039% |  |
11/13/2024 | FMR LLC | 6,573 | $46K | 0.0% | N/A | 0.020% |  |
9/16/2024 | Point72 DIFC Ltd | 4,927 | $31K | 0.0% | N/A | 0.017% |  |
9/16/2024 | Cubist Systematic Strategies LLC | 26,121 | $0.16M | 0.0% | N/A | 0.088% |  |
8/14/2024 | Cubist Systematic Strategies LLC | 26,121 | $0.16M | 0.0% | N/A | 0.088% |  |
8/14/2024 | Point72 DIFC Ltd | 4,927 | $31K | 0.0% | N/A | 0.017% |  |
8/13/2024 | Sands Capital Ventures LLC | 405,837 | $2.52M | 0.8% | -50.0% | 1.364% |  |
8/9/2024 | Renaissance Technologies LLC | 20,600 | $0.13M | 0.0% | -63.8% | 0.069% |  |
8/1/2024 | Rhumbline Advisers | 22,985 | $0.14M | 0.0% | N/A | 0.077% |  |
7/26/2024 | Bank of New York Mellon Corp | 54,449 | $0.34M | 0.0% | N/A | 0.183% |  |
1/29/2024 | Baystate Wealth Management LLC | 76,910 | $0.11M | 0.0% | -21.0% | 0.266% |  |
5/10/2023 | Resources Investment Advisors LLC. | 25,428 | $34K | 0.0% | N/A | 0.088% |  |
4/25/2023 | Baystate Wealth Management LLC | 105,854 | $0.14M | 0.0% | N/A | 0.366% |  |
11/14/2022 | Point72 Asset Management L.P. | 403,131 | $1.27M | 0.0% | -45.7% | 1.395% |  |
5/6/2022 | Empirical Asset Management LLC | 12,000 | $61K | 0.1% | N/A | 0.042% |  |
4/26/2022 | Kestra Advisory Services LLC | 12,500 | $64K | 0.0% | N/A | 0.044% |  |
2/15/2022 | Northpond Ventures LLC | 1,935,215 | $15.13M | 5.3% | N/A | 6.745% |  |
2/15/2022 | 683 Capital Management LLC | 40,929 | $0.32M | 0.0% | N/A | 0.143% |  |
11/15/2021 | Caas Capital Management LP | 50,000 | $0.54M | 0.0% | N/A | 0.174% |  |
11/15/2021 | Franklin Resources Inc. | 1,125,000 | $12.20M | 0.0% | N/A | 3.921% |  |
11/9/2021 | BlackRock Inc. | 22,326 | $0.24M | 0.0% | N/A | 0.078% |  |
Data available starting January 2016
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Read More on Candel Therapeutics
Volume
786,771 shs
Average Volume
1,142,762 shs
Market Capitalization
$293.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Candel Therapeutics?
Candel Therapeutics' top insider shareholders include:
- Paul B Manning (Director)
- Estuardo Aguilar-Cordova (Major Shareholder)
- Paul Peter Tak (CEO)
- Seshu Tyagarajan (CTO)
- Francesca Barone (Insider)
- William Garrett Nichols (Insider)
- Charles Schoch (Insider)
Learn More about top insider investors at Candel Therapeutics.
Who are the major institutional investors of Candel Therapeutics?
Which major investors are selling Candel Therapeutics stock?
In the previous quarter, CADL stock was sold by these institutional investors:
- Vontobel Holding Ltd.
During the last year, company insiders that have sold Candel Therapeutics company stock include:
- Paul B Manning (Director)
- Estuardo Aguilar-Cordova (Major Shareholder)
- Paul Peter Tak (CEO)
- Seshu Tyagarajan (CTO)
- Francesca Barone (Insider)
- William Garrett Nichols (Insider)
Learn More investors selling Candel Therapeutics stock.
Which major investors are buying Candel Therapeutics stock?
Within the last quarter, CADL stock was purchased by institutional investors including:
- Portolan Capital Management LLC
- Halter Ferguson Financial Inc.
- Susquehanna International Group LLP
- Rosalind Advisors Inc.
- Birchview Capital LP
- Commonwealth Equity Services LLC
- Oppenheimer & Co. Inc.
- Diadema Partners LP